Physician profile
Amanda Carter
NPI 1093376709
$1,811.17
in general payments reported to CMS, 2019-2025
21 companies · $999 in 2025
The $999 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.64 · 2023: $233 · 2024: $561 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.53 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $218.88 | 2024-2025 | |
| Boston Scientific Corporation | $199.82 | 2023-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Wavewriter Alpha Prime 16 |
| Novartis Pharmaceuticals Corporation | $198.49 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $195.65 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $150.46 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $129.90 | 2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $108.70 | 2022-2025 | Verquvo |
| Amgen INC. | $92.94 | 2023-2025 | Repatha, Repatha |
| United Therapeutics Corporation | $92.41 | 2024-2025 | Tyvaso, Remodulin, Orenitram |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.79 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $57.73 | 2023-2024 | Farxiga, Wainua |
| Cvrx, INC. | $51.67 | 2025 | Barostim Neo System |
| Pfizer INC. | $43.05 | 2024-2025 | |
| Abbott Laboratories | $41.65 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Scpharmaceuticals INC. | $28.28 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $22.27 | 2024 | |
| Alnylam Pharmaceuticals INC. | $20.33 | 2024 | Onpattro |
| Glaxosmithkline, LLC. | $19.55 | 2025 | Shingrix, Arexvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.34 | 2024 | Lifevest |
| Novo Nordisk INC | $17.22 | 2024 | Ozempic |
| Janssen Pharmaceuticals, INC | $17.04 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.